Short-Term Steroid Bursts Linked to Serious Risks in Type 2 Diabetes Patients

Short-term courses of oral corticosteroids prescribed for common inflammatory and respiratory conditions are linked to an increased risk of serious adverse events among patients with type 2 diabetes, according to an analysis published in JAMA Network Open. While brief steroid bursts are widely considered safe, investigators found that patients experienced elevated 30-day risks of pneumonia, heart failure, and gastrointestinal bleeding after beginning treatment.

Led by Tsung-Chieh Yao, MD, PhD, of Chang Gung Memorial Hospital in Taiwan, researchers evaluated data from Taiwan’s National Health Insurance Research Database between 2008 and 2022. The study analyzed 36,048 adult patients with type 2 diabetes who received oral corticosteroid bursts, defined as continuous use for 14 days or less, with a mean duration of 4.5 days. Among the cohort, 52.4% were women, and the mean age was 61.6 years.

Family practice providers accounted for 24.1% of the corticosteroid prescriptions, followed by dermatology at 22.5%, internal medicine at 15.9%, and otolaryngology at 13%. Using a self-controlled case series design, the investigators compared adverse event rates during exposed periods against baseline windows to track sudden health vulnerabilities in this patient population.

Short-Term Steroid Risks Emerge Within Thirty Days

The analysis revealed that excess health risks peaked within the first 30 days following the start of an oral corticosteroid burst. Patients faced a pneumonia incidence rate ratio of 2.06, more than double the baseline risk, alongside an incidence rate ratio of 1.87 for heart failure and 1.71 for gastrointestinal tract bleeding.

Additional safety signals during the initial 30-day window included an elevated risk for sepsis at an incidence rate ratio of 1.57 and bone fracture at 1.30. The magnitude of the pneumonia risk underscores how even brief steroid exposure can trigger severe complications in individuals who already carry heightened cardiometabolic vulnerabilities.

Lingering Complications Beyond the First Month

Certain health risks persisted long after patients finished their short steroid courses. Between 31 and 90 days post-initiation, researchers observed continued elevations in gastrointestinal tract bleeding with an incidence rate ratio of 1.26, as well as an increased risk for fractures at an incidence rate ratio of 1.42.

To validate these outcomes, the study team conducted multiple sensitivity analyses. These tests accounted for alternative corticosteroid burst definitions up to 30 days, the exclusion of death events, and different washout windows. The results remained consistent across all models, and no significant association appeared for the negative control outcome of syncope.

Clinical Implications for Type 2 Diabetes Management

While medical guidelines routinely advise close blood glucose monitoring when initiating oral corticosteroids due to steroid-induced hyperglycemia, secondary systemic risks have remained less examined. The study authors noted that patients with type 2 diabetes enter treatment with pre-existing vulnerabilities to infections, cardiovascular events, and skeletal complications.

From a clinical perspective, these findings underscore the importance of judicious OCS prescribing in patients with type 2 diabetes, particularly for self-limited conditions for which alternative therapies are available. The researchers acknowledged several limitations in their work, including an inability to verify exact patient medication adherence, a lack of detailed lifestyle data in the administrative registry, and potential constraints on generalizing the results to non-Asian populations. Despite these limitations, the authors emphasize that physicians should carefully weigh potential harms against expected benefits before prescribing oral corticosteroids to patients managing type 2 diabetes.